Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1470

Shown on this page

Current sort

Live official records

Conditions: Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
Interventions: Nephrectomy, Nivolumab, Patient Observation, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 396
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more

Conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 532
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more

Conditions: Multiple Myeloma
Interventions: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more

Conditions: Blunt Trauma to Abdomen, Wounds and Injuries, Abdomen Injury, Abdominal Injury, Abdomen, Acute
Interventions: Focused Assessment with Sonography for Trauma (FAST) Examination, No Intervention: Standard of Care - Without the FAST Examination; Diagnostic Test · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 4,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Interventions: Patritumab Deruxtecan, Platinum-based chemotherapy; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 23
States / cities: Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more

Conditions: Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
Interventions: Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment; Other · Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Interventions: olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar); Biological · Drug
Lead sponsor: Genelux Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 33
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Interventions: avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer, Advanced Colorectal Cancer
Interventions: CBI-1214; Biological
Lead sponsor: Cartography Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more

Conditions: Hip Fractures, Myocardial Injury
Interventions: Accelerated medical clearance and surgery; Other
Lead sponsor: Population Health Research Institute; Other
Eligibility: 45 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Chandler, Arizona • Davis, California • Irvine, California + 19 more

Conditions: Obstructive Sleep Apnea
Interventions: Negative Pressure Ventilator, Pulmonary Function Testing (PFT), Transcutaneous Phrenic Nerve Stimulation, Percutaneous Phrenic Nerve Stimulation; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

About this Emory University (Winship Cancer Institute) institution page

What this page lists: ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Emory University (Winship Cancer Institute)

Filter and sort this campus

Live official records

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

Effects of Lung Volume on Upper Airway Patency During Drug Induced Sleep Endoscopy

About this Emory University (Winship Cancer Institute) institution page